Results 251 to 260 of about 46,788 (276)
Some of the next articles are maybe not open access.
Ofatumumab and Granzyme B as immunotoxin against CD20 antigen
In Silico Pharmacology, 2022Anti-CD20 antibodies such as ofatumumab has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. In this study, we have designed an immunotoxin composed of Granzyme B and the high affinity variant of Ofatumumab.
Fateme Sefid +6 more
openaire +2 more sources
CD20: A target antigen for immunotherapy of autoimmune diseases
Autoimmunity Reviews, 2005This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases.
PEROSA, Federico +4 more
openaire +4 more sources
Development of a Mimotope-Based Vaccine Against CD20 Antigen
Protein & Peptide Letters, 2007CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to ...
Meng Li +5 more
openaire +3 more sources
Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia
American Journal of Hematology, 1992AbstractThe surface antigens expressed by the cells of chronic lymphocytic leukemia (CLL) are well known. Most CLL are monoclonal B‐cell lymphoproliferative disorders characterized by the coexpression of B‐cell antigens and CD5, an antigen present predominantly on T cells.
Ricardo E. Duque +4 more
openaire +3 more sources
Analysis of cis-acting elements present in the CD20/B1 antigen promoter
The Journal of Immunology, 1991Abstract A genomic clone spanning a large portion of the 5’ untranscribed region of the CD20 gene was isolated. Deletion analysis of subcloned fragments identified several regulatory elements. A major positive cis-acting element was localized between base pairs -290/-186.
P, Rieckmann +4 more
openaire +2 more sources
Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
International Journal of Radiation Oncology*Biology*Physics, 2004The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially ...
M.Carmen Hernandez, Susan J. Knox
openaire +2 more sources
Cancer Biotherapy and Radiopharmaceuticals, 2015
The rapid expansion of immunotherapeutic approaches for treatment of various diseases, including cancers, has been greatly facilitated by the invention of new generation of antibodies. Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20 on their cell ...
Ensiyeh Hajizadeh-Saffar +5 more
openaire +3 more sources
The rapid expansion of immunotherapeutic approaches for treatment of various diseases, including cancers, has been greatly facilitated by the invention of new generation of antibodies. Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20 on their cell ...
Ensiyeh Hajizadeh-Saffar +5 more
openaire +3 more sources
Immunological evaluation of predicted linear B‐cell epitopes of human CD20 antigen
Biotechnology and Applied Biochemistry, 2012AbstractThe importance of B‐lymphocyte‐restricted differentiation antigen Bp35 (CD20) as a target for immunotherapeutic depletion of B cells is irrefutable. Several anti‐human CD20 (anti‐hCD20) monoclonal antibodies are expressed at different stages of development.
Mahdi Behdani +8 more
openaire +3 more sources
The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders [PDF]
Expert Opinion on Biological Therapy, 2011 Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic
Musto P, D'Auria F
openaire +2 more sources
Langmuir, 2015
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Rituximab is a chimeric therapeutic monoclonal antibody (mAb) against the protein CD20, allowing it to destroy B cells and to treat lymphoma, leukemia, transplant rejection, and autoimmune disorder.
Norman Leo +4 more
openaire +3 more sources
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Rituximab is a chimeric therapeutic monoclonal antibody (mAb) against the protein CD20, allowing it to destroy B cells and to treat lymphoma, leukemia, transplant rejection, and autoimmune disorder.
Norman Leo +4 more
openaire +3 more sources